VIRATEK's VIRAZOLE FOR SEVERE LOWER RESPIRATORY INFECTIONS IS TARGETED AT APPROXIMATELY 100,000 YOUNG CHILDREN PER YEAR; FDA APPROVES ANTIVIRAL DRUG JAN. 2